Citation 1:
    Title: lly-20231231
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/lly-20231231.htm#:~:text=Dividends%20of%20%244,20%20per%20share
    Location: chars 429–574

Citation 2:
    Title: lly-20250331
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/lly-20250331.htm#:~:text=The%20number%20of%20shares%20of,outstanding%20as%20of%20April%C2%A028%2C%202025
    Location: chars 601–787

Citation 3:
    Title: lly-20231231
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/lly-20231231.htm#:~:text=Cash%20and%20cash%20equivalents%20,2%2C067.0
    Location: chars 1018–1169

Citation 4:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=,0%20billion
    Location: chars 1375–1534

Citation 5:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=Gross%20margin%20increased%2048,offset%20by%20lower%20realized%20prices
    Location: chars 1569–1787

Citation 6:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=obesity%20and%20diabetes%20Phase%203,0%20billion
    Location: chars 1819–2014

Citation 7:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=Net%20income%20%E2%80%93%20Reported%20,23
    Location: chars 2130–2318

Citation 8:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=Revenue%20in%20the%20U,driven%20by%20Zepbound%20and%20Mounjaro
    Location: chars 2383–2592

Citation 9:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=obesity%20and%20diabetes%20Phase%203,0%20billion
    Location: chars 2655–2850

Citation 10:
    Title: Lilly reports full Q4 2024 financial results and provides 2025 guidance | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025#:~:text=,to%20%245.32
    Location: chars 2878–3048

Citation 11:
    Title: Lilly reports full Q4 2024 financial results and provides 2025 guidance | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025#:~:text=,00
    Location: chars 3097–3257

Citation 12:
    Title: Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically#:~:text=Orforglipron%20is%20the%20first%20small,across%20doses
    Location: chars 3415–3619

Citation 13:
    Title: Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lillys-jaypirca-pirtobrutinib-recommended-chmp-approval-european#:~:text=INDIANAPOLIS%2C%20Feb,treated%20with%20a%20BTK%20inhibitor
    Location: chars 3680–3897

Citation 14:
    Title: Lilly reports full Q4 2024 financial results and provides 2025 guidance | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025#:~:text=,of%20early%20symptomatic%20Alzheimer%27s%20disease
    Location: chars 4088–4296

Citation 15:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=In%20Q1%202025%2C%20research%20and,stage%20portfolio
    Location: chars 4352–4551

Citation 16:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=Marketing%2C%20selling%20and%20administrative%20expenses,supporting%20ongoing%20and%20future%20launches
    Location: chars 4622–4872

Citation 17:
    Title: lly-20231231
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/lly-20231231.htm#:~:text=Cash%20and%20cash%20equivalents%20,2%2C067.0
    Location: chars 5016–5167

Citation 18:
    Title: Lilly Sells $6.5 Billion of Bonds for Cancer Drug Purchase - Bloomberg
    URL: https://www.bloomberg.com/news/articles/2025-02-10/eli-lilly-taps-high-grade-market-to-fund-cancer-drug-purchase#:~:text=Eli%20Lilly%20%26%20Co,cancer%20drug%20from%20%2021
    Location: chars 5245–5440

Citation 19:
    Title: lly-20250331
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/lly-20250331.htm#:~:text=The%20number%20of%20shares%20of,outstanding%20as%20of%20April%C2%A028%2C%202025
    Location: chars 5512–5698

Citation 20:
    Title: lly-20231231
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/lly-20231231.htm#:~:text=Number%20of%20shares%20of%20common,as%20of%20February%C2%A016%2C%202024%3A%20950%2C164%2C452
    Location: chars 5699–5898

Citation 21:
    Title: lly-20231231
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/lly-20231231.htm#:~:text=Dividends%20of%20%244,20%20per%20share
    Location: chars 5954–6099

Citation 22:
    Title: Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically#:~:text=complete%20a%20Phase%203%20trial,1
    Location: chars 6491–6675

Citation 23:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=,0%20billion
    Location: chars 7710–7869

Citation 24:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=obesity%20and%20diabetes%20Phase%203,0%20billion
    Location: chars 7892–8087

Citation 25:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=obesity%20and%20diabetes%20Phase%203,0%20billion
    Location: chars 8128–8323

Citation 26:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=Gross%20margin%20increased%2048,offset%20by%20lower%20realized%20prices
    Location: chars 8356–8574

Citation 27:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=In%20Q1%202025%2C%20research%20and,stage%20portfolio
    Location: chars 8595–8794

Citation 28:
    Title: Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically#:~:text=Orforglipron%20is%20the%20first%20small,across%20doses
    Location: chars 8895–9099

Citation 29:
    Title: Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lillys-jaypirca-pirtobrutinib-recommended-chmp-approval-european#:~:text=INDIANAPOLIS%2C%20Feb,treated%20with%20a%20BTK%20inhibitor
    Location: chars 9294–9511

Citation 30:
    Title: Lilly reports full Q4 2024 financial results and provides 2025 guidance | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025#:~:text=,of%20early%20symptomatic%20Alzheimer%27s%20disease
    Location: chars 9644–9852

Citation 31:
    Title: Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
    URL: https://www.prnewswire.com/news-releases/lilly-to-expand-its-pain-pipeline-with-acquisition-of-siteone-therapeutics-302465735.html#:~:text=Under%20the%20terms%20of%20the,certain%20regulatory%20and%20commercial%20milestones
    Location: chars 9990–10236

Citation 32:
    Title: Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics - BioSpace
    URL: https://www.biospace.com/press-releases/lilly-to-expand-its-pain-pipeline-with-acquisition-of-siteone-therapeutics#:~:text=Under%20the%20terms%20of%20the,certain%20regulatory%20and%20commercial%20milestones
    Location: chars 10237–10465

Citation 33:
    Title: Lilly Sells $6.5 Billion of Bonds for Cancer Drug Purchase - Bloomberg
    URL: https://www.bloomberg.com/news/articles/2025-02-10/eli-lilly-taps-high-grade-market-to-fund-cancer-drug-purchase#:~:text=Eli%20Lilly%20%26%20Co,cancer%20drug%20from%20%2021
    Location: chars 10556–10751

Citation 34:
    Title: Novo Nordisk cuts Wegovy prices, following Eli Lilly on Zepbound | PBS News
    URL: https://www.pbs.org/newshour/health/novo-nordisk-cuts-wegovy-prices-following-eli-lilly-on-zepbound#:~:text=Last%20week%2C%20Eli%20Lilly%20said,pay%20program
    Location: chars 10888–11062

Citation 35:
    Title: Lilly reports full Q4 2024 financial results and provides 2025 guidance | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025#:~:text=,00
    Location: chars 11198–11358

Citation 36:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=In%20Q1%202025%2C%20worldwide%20revenue,led%20by%20Mounjaro%20and%20Zepbound
    Location: chars 11556–11779

Citation 37:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=In%20Q1%202025%2C%20worldwide%20revenue,led%20by%20Mounjaro%20and%20Zepbound
    Location: chars 11989–12212

Citation 38:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=Gross%20margin%20increased%2048,offset%20by%20lower%20realized%20prices
    Location: chars 12409–12627

Citation 39:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=obesity%20and%20diabetes%20Phase%203,0%20billion
    Location: chars 12944–13139

Citation 40:
    Title: Lilly reports full Q4 2024 financial results and provides 2025 guidance | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025#:~:text=Net%20income%20%20,102
    Location: chars 13258–13437

Citation 41:
    Title: Lilly reports full Q4 2024 financial results and provides 2025 guidance | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025#:~:text=,00
    Location: chars 13473–13633

Citation 42:
    Title: lly-20231231
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/lly-20231231.htm#:~:text=Revenue%20%28Note%202%29%20%20,28%2C318.4
    Location: chars 14296–14444

Citation 43:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=,0%20billion
    Location: chars 14445–14604

Citation 44:
    Title: Novo Nordisk Market Cap 2010-2025 | NVO | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/market-cap#:~:text=Novo%20Nordisk%20market%20cap%20history,14B
    Location: chars 14991–15137

Citation 45:
    Title: Novo Nordisk EPS - Earnings per Share 2010-2025 | NVO | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/eps-earnings-per-share-diluted#:~:text=,increase%20from%202022
    Location: chars 15146–15292

Citation 46:
    Title: Novo Nordisk Market Cap 2010-2025 | NVO | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/market-cap#:~:text=Stock%20Name%20%20,7.72
    Location: chars 15360–15486

Citation 47:
    Title: Novo Nordisk Market Cap 2010-2025 | NVO | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/market-cap#:~:text=Eli%20Lilly%20,0.00
    Location: chars 15554–15676

Citation 48:
    Title: AbbVie EPS - Earnings per Share 2010-2025 | ABBV | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/ABBV/abbvie/eps-earnings-per-share-diluted#:~:text=,year
    Location: chars 15686–15809

Citation 49:
    Title: Novo Nordisk Market Cap 2010-2025 | NVO | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/market-cap#:~:text=Novartis%20AG%20,7.72
    Location: chars 15870–15994

Citation 50:
    Title: Merck EPS - Earnings per Share 2010-2025 | MRK | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/MRK/merck/eps-earnings-per-share-diluted#:~:text=,year
    Location: chars 16004–16125

Citation 51:
    Title: Novo Nordisk Market Cap 2010-2025 | NVO | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/market-cap#:~:text=Novartis%20AG%20,7.72
    Location: chars 16186–16310

Citation 52:
    Title: Pfizer EPS - Earnings per Share 2010-2025 | PFE | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/PFE/PFE/eps-earnings-per-share-diluted#:~:text=,year
    Location: chars 16320–16439

Citation 53:
    Title: Novo Nordisk Market Cap 2010-2025 | NVO | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/market-cap#:~:text=Eli%20Lilly%20,7.72
    Location: chars 16716–16838

Citation 54:
    Title: lly-20231231
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/lly-20231231.htm#:~:text=Cash%20and%20cash%20equivalents%20,2%2C067.0
    Location: chars 17146–17297

Citation 55:
    Title: lly-20231231
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/lly-20231231.htm#:~:text=Dividends%20of%20%244,20%20per%20share
    Location: chars 17527–17672

Citation 56:
    Title: lly-20231231
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/lly-20231231.htm#:~:text=Number%20of%20shares%20of%20common,as%20of%20February%C2%A016%2C%202024%3A%20950%2C164%2C452
    Location: chars 17826–18025

Citation 57:
    Title: GLP-1 Receptor Agonists: Drug Litigation Overview and Trends | Foley & Lardner LLP
    URL: https://www.foley.com/insights/publications/2025/04/glp-1-receptor-agonists-drug-litigation-overview-trends/#:~:text=The%20recent%20uptick%20and%20rise,declared%20drug%20shortages
    Location: chars 18795–18993

Citation 58:
    Title: Novo Nordisk cuts Wegovy prices, following Eli Lilly on Zepbound | PBS News
    URL: https://www.pbs.org/newshour/health/novo-nordisk-cuts-wegovy-prices-following-eli-lilly-on-zepbound#:~:text=Last%20week%2C%20Eli%20Lilly%20said,pay%20program
    Location: chars 19627–19801

Citation 59:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=In%20Q1%202025%2C%20worldwide%20revenue,52%20billion
    Location: chars 19934–20133

Citation 60:
    Title: Eli Lilly PE Ratio 2010-2025 | LLY | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/LLY/LLY/pe-ratio#:~:text=Date%20%20,110.74
    Location: chars 21422–21531

Citation 61:
    Title: Novo Nordisk Market Cap 2010-2025 | NVO | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/market-cap#:~:text=Eli%20Lilly%20,7.72
    Location: chars 21690–21812

Citation 62:
    Title: Novo Nordisk Market Cap 2010-2025 | NVO | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/market-cap#:~:text=Eli%20Lilly%20,7.72
    Location: chars 22167–22289

Citation 63:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=,0%20billion
    Location: chars 23159–23318

Citation 64:
    Title: lly-20231231
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/lly-20231231.htm#:~:text=2022%20%20,28%2C318.4
    Location: chars 23319–23447

Citation 65:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=,0%20billion
    Location: chars 23520–23679

Citation 66:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=Earnings%20per%20share%20%E2%80%93%20Reported,29
    Location: chars 23680–23875

Citation 67:
    Title: Lilly reports full Q4 2024 financial results and provides 2025 guidance | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025#:~:text=,to%20%245.32
    Location: chars 23961–24131

Citation 68:
    Title: Lilly reports full Q4 2024 financial results and provides 2025 guidance | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025#:~:text=,00
    Location: chars 24132–24292

Citation 69:
    Title: Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically#:~:text=Orforglipron%20is%20the%20first%20small,across%20doses
    Location: chars 24371–24575

Citation 70:
    Title: Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lillys-jaypirca-pirtobrutinib-recommended-chmp-approval-european#:~:text=INDIANAPOLIS%2C%20Feb,treated%20with%20a%20BTK%20inhibitor
    Location: chars 24644–24861

Citation 71:
    Title: Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
    URL: https://www.prnewswire.com/news-releases/lilly-to-expand-its-pain-pipeline-with-acquisition-of-siteone-therapeutics-302465735.html#:~:text=Under%20the%20terms%20of%20the,certain%20regulatory%20and%20commercial%20milestones
    Location: chars 24957–25203

Citation 72:
    Title: Lilly Sells $6.5 Billion of Bonds for Cancer Drug Purchase - Bloomberg
    URL: https://www.bloomberg.com/news/articles/2025-02-10/eli-lilly-taps-high-grade-market-to-fund-cancer-drug-purchase#:~:text=Eli%20Lilly%20%26%20Co,cancer%20drug%20from%20%2021
    Location: chars 25285–25480

Citation 73:
    Title: Novo Nordisk cuts Wegovy prices, following Eli Lilly on Zepbound | PBS News
    URL: https://www.pbs.org/newshour/health/novo-nordisk-cuts-wegovy-prices-following-eli-lilly-on-zepbound#:~:text=Last%20week%2C%20Eli%20Lilly%20said,pay%20program
    Location: chars 25567–25741

Citation 74:
    Title: Novo Nordisk EPS - Earnings per Share 2010-2025 | NVO | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/eps-earnings-per-share-diluted#:~:text=,increase%20from%202022
    Location: chars 25782–25928

Citation 75:
    Title: Merck EPS - Earnings per Share 2010-2025 | MRK | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/MRK/merck/eps-earnings-per-share-diluted#:~:text=,year
    Location: chars 25947–26068

Citation 76:
    Title: Pfizer EPS - Earnings per Share 2010-2025 | PFE | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/PFE/PFE/eps-earnings-per-share-diluted#:~:text=,year
    Location: chars 26089–26208

Citation 77:
    Title: AbbVie EPS - Earnings per Share 2010-2025 | ABBV | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/ABBV/abbvie/eps-earnings-per-share-diluted#:~:text=,year
    Location: chars 26229–26352

Citation 78:
    Title: Novo Nordisk Market Cap 2010-2025 | NVO | MacroTrends
    URL: https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/market-cap#:~:text=Stock%20Name%20%20,7.72
    Location: chars 26387–26513

Citation 79:
    Title: GLP-1 Receptor Agonists: Drug Litigation Overview and Trends | Foley & Lardner LLP
    URL: https://www.foley.com/insights/publications/2025/04/glp-1-receptor-agonists-drug-litigation-overview-trends/#:~:text=The%20recent%20uptick%20and%20rise,declared%20drug%20shortages
    Location: chars 26617–26815

Citation 80:
    Title: lly-20231231
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/lly-20231231.htm#:~:text=Dividends%20of%20%244,20%20per%20share
    Location: chars 26863–27008

Citation 81:
    Title: lly-20231231
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/lly-20231231.htm#:~:text=Cash%20and%20cash%20equivalents%20,2%2C067.0
    Location: chars 27009–27160

Citation 82:
    Title: lly-20250331
    URL: https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/lly-20250331.htm#:~:text=The%20number%20of%20shares%20of,outstanding%20as%20of%20April%C2%A028%2C%202025
    Location: chars 27202–27388

